Medication Description: Astemizole
Astemizole (Astemizole) *. 1- (p-fluorobenzyl) -2 - [[1- (p-methoxyphenylethyl) -4-piperidyl] amino] benzimidazole.
Synonyms: Gismanal, Alermizol, Astelong, Hismanal, Histamanal, Ifirab, Lembil, Stemiz, Vagran.
The blocker H 1 -histamine receptors.
It does not bind to muscarinic and dopamine receptors; it has a weak antiserotonin activity. It does not have a sedative effect, does not potentiate the action of sleeping pills and sedatives, analgesics.
Differs in high activity and duration of action. When ingested quickly absorbed. Peak plasma concentrations are observed 1–4 hours after administration. Removal from the body lasts up to 10 - 14 days.
Partially unchanged astemizole and its metabolites are excreted mainly in the feces. Through the blood-brain barrier does not penetrate.
Bioavailability of astemizole is reduced when taken with food.
Used to treat seasonal rhinitis (pollinosis), allergic conjunctivitis, pruritus and other allergic manifestations.
Assign adults and children over 12 years old at a dose of 10 mg (0.01 g) 1 time per day on an empty stomach. If necessary, increase the daily dose to 30 mg. The maximum period of taking the drug is 7 days.
Children aged 6 to 12 years give 5 mg per day (1/2 tablet); if necessary, 15 mg daily, for a maximum of 7 days. Children under 6 years old - 2 mg (2 ml of suspension) per 10 kg of body weight.
When taking astemizole, side effects are usually not observed, but an increase in appetite with an increase in body weight is possible.
During pregnancy, the drug is not prescribed.
Astemizol does not affect the action of corticosteroids, antibiotics, sulfonamides, diuretics, analgesics, cardiovascular drugs.
Method of production: tablets of 0.01 g (10 mg) in a package of 10 pieces; suspension, containing in 5 ml (1 teaspoon) 0.005 g (5 mg) of the drug, in vials of 50 ml.
Storage: List B.